0001628280-24-030175.txt : 20240626 0001628280-24-030175.hdr.sgml : 20240626 20240626164252 ACCESSION NUMBER: 0001628280-24-030175 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240626 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20240626 DATE AS OF CHANGE: 20240626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Augmedix, Inc. CENTRAL INDEX KEY: 0001769804 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 833299164 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40890 FILM NUMBER: 241074190 BUSINESS ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 561-989-2208 MAIL ADDRESS: STREET 1: 111 SUTTER STREET, SUITE 1300 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Malo Holdings Corp DATE OF NAME CHANGE: 20190305 8-K 1 augx-20240626.htm 8-K augx-20240626
false000176980400017698042024-06-262024-06-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 26, 2024
AUGMEDIX, INC.
(Exact name of registrant as specified in its charter)
Delaware001-4089083-3299164
(State or other jurisdiction
 of incorporation)
(Commission File Number)
(I.R.S. Employer
 Identification No.)
111 Sutter Street, Suite 1300, San Francisco, California 94104
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (888) 669-4885
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:☒
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareAUGXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 1.01. Entry into a Material Definitive Agreement.
Entry into Second Amendment to Loan and Security Agreement

On June 26, 2024 (the “Effective Date”), Augmedix, Inc., a Delaware corporation (the “Company”) and Augmedix Operating Corporation, a Delaware corporation (“OpCo”), each entered into that certain Second Amendment to Loan and Security Agreement (the “Amendment”) by and among the Company and OpCo as borrowers (individually and collectively, “Borrower”) and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Lender”) which amends certain provisions of the Loan and Security Agreement by and among Borrower and Lender dated as of May 4, 2022 as amended by the First Amendment to Loan and Security Agreement dated as of June 13, 2023 (“Existing LSA”).

The Amendment provides for, among other things:

Term Loan Facility:

Under the Existing LSA, the term loan facility’s stated maturity date is June 1, 2025, provided that, if Borrower achieves certain performance and equity milestones, the term loan facility maturity date will automatically be extended to December 1, 2025. The Amendment extends the term loan facility’s stated maturity date to December 1, 2026.

Under the Existing LSA, the term loan facility is interest only until July 1, 2023, provided that if Borrower achieves certain performance and equity milestones, the amortization date automatically extends to January 1, 2024. The Amendment extends the interest only period applicable to the term loan facility until January 1, 2025 and provides that the interest only period may be extended by Lender in its sole and absolute discretion to July 1, 2025.

Revolving Credit Facility:

Under the Existing LSA, the stated maturity date for the revolving credit facility is November 4, 2024. The Amendment provides that the maturity date for the revolving credit facility may be extended by the Lender in its sole and absolute discretion to November 4, 2025.

The Amendment requires the Borrower to maintain $5,000,000 in a cash collateral account maintained with the Lender and pledged in favor of the Lender.

In connection with the Existing LSA, the Company issued to Lender a warrant to purchase up to 190,330 shares of the Company’s common stock, at an exercise price of $3.01 per share (the “Existing Warrant”). In connection with the Amendment, the Lender required the Company to amend the Existing Warrant, to, among other things, reduce the exercise price under the Existing Warrant to $1.09 per share, pursuant to the First Amendment to Warrant to Purchase Stock (the “Warrant Amendment”).

The foregoing summaries of the Amendment and the Warrant Amendment are not complete and are qualified in their entirety by reference to the full text of the form of the Amendment and the Warrant Amendment attached hereto as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.Description
4.1
10.1
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
1


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AUGMEDIX, INC.
Dated: June 26, 2024By:/s/ Paul Ginocchio
Paul Ginocchio
Chief Financial Officer
2
EX-4.1 2 exhibit_4x1xfirstamendment.htm EX-4.1 Document

FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK
This FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK (this “Amendment”) is made as of June 26, 2024 by and between FIRST CITIZENS EQUITY INVESTMENTS, LLC (“Holder”) and AUGMEDIX, INC., a Delaware corporation (“Company”).
RECITALS
A.    Company and SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (“SVB”) executed a Warrant to Purchase Stock dated as of June 13, 2023 (as amended, and as may be further amended, restated, amended and restated, modified, or supplemented from time to time, the “Warrant”). Pursuant to the terms and conditions in the Warrant, SVB transferred its interest in the Warrant to Holder.
B.    Company and Holder wish to amend the Warrant to make certain revisions to the Warrant as more fully set forth herein.
NOW, THEREFORE, for good and valuable consideration, the receipt and legal sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
1.Schedule I (Warrant Provisions) appearing on the first page of the Warrant is hereby amended and restated in its entirety and replaced with the following:
Warrant SectionWarrant Provision
Recitals – “Issue Date”June 13, 2023.
Recitals – “Company”
AUGMEDIX, INC., a Delaware corporation.
1.1 – “Class”Common Stock, $0.0001 par value per share.
1.1 – “Exercise Price”$1.09 per Share.
1.2 – “Shares”190,330.
4.1(b) – Share percentage as of the Issue Date0.42% of the Company’s total fully-diluted issued and outstanding shares of capital stock.
6.1(a) – “Expiration Date”June 13, 2030.

2.Section 1.3 of the Warrant is hereby amended and restated in its entirety and replaced with the following:
Reserved.”
3.New Section 2.7 hereby is added to the Warrant to read in its entirety as follows:
“2.7    BHCA Limitations. Notwithstanding any contrary provision herein, in no event may this Warrant be exercisable, in whole or in part, for or into a number of Shares in excess of the number of Shares that would result in Holder’s ownership of Shares, when combined with any other interest in the Company held by Holder and any FCB Affiliate, equaling:  (1) 33.32% of the Company’s “total equity”, as calculated in accordance with the Bank Holding Company Act of 1956, as amended (the “BHCA”), and any regulations, guidance and interpretations promulgated thereunder, including 12 CFR Part 225; or (2) 4.99% of any class of “voting securities” of the

Active\1609095006.2


Company, as determined in accordance with the BHCA and any regulations, guidance and interpretations promulgated thereunder, including 12 CFR Part 225 (clauses (1) and (2) together, the “BHCA Limits”).  To the extent the Holder would be, absent this section, entitled to receive Shares under this Warrant in excess of the BHCA Limits, Holder shall receive the right to cash consideration for the excess Shares, calculated in a manner consistent with this Section 2. The BHCA Limits shall apply to any transferee in receipt of this Warrant unless any such transfer to a transferee is made in a manner described under 12 CFR §225.9(a)(3)(ii). As used herein, “FCB Affiliate” means any entity that is controlled by, under the control of, or under common control with the Holder, with the term “control” as defined under the BHCA and regulations, guidance and interpretations promulgated thereunder.”
4.Section 4.4 of the Warrant is hereby amended and restated in its entirety and replaced with the following:
Reserved.”
5.Section 6.4 of the Warrant hereby is amended and restated in its entirety to read as follows:
“6.4    Transfer Procedure.
(a)    Subject to the provisions of Section 6.3 and upon providing the Company with written notice, Holder (including any subsequent Holder) may transfer all or part of this Warrant or the Shares issued upon exercise of this Warrant to any transferee; provided that in connection with any such transfer: (i) Holder will give the Company notice of the portion of the Warrant and/or Shares being transferred with the name, address and taxpayer identification number of the transferee; (ii) Holder will surrender this Warrant, or the certificates or other evidence of such Shares or other securities, to the Company for reissuance to the transferee(s) (and to Holder if applicable); and (iii) any subsequent transferee shall make substantially the representations set forth in Section 5.1 above and shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant; and provided further, that the transfer of any Shares issued on exercise hereof shall be subject to the provisions of the Charter Documents and any stockholder agreements to the extent Holder is then a party thereto or otherwise subject thereto in accordance with the provisions of Section 5.4 above.
(b)    In the event of any transfer to an FCB Affiliate, the transfer requirements set forth in Section 6.4(a) above shall be satisfied by Holder delivering to the Company a Notice of Transfer in substantially the form attached hereto as Appendix 2; provided that: (i) Holder will not be required to surrender this Warrant pursuant to Section 6.4(a)(ii); (ii) the Company will note such FCB Affiliate as the Holder in the Company’s records and, as applicable, with any transfer agent; and (iii) such FCB Affiliate will otherwise be deemed to be the “Holder” of this Warrant with respect to the transferred portion thereof. Such Notice of Transfer shall be deemed delivered and effective in accordance with Section 6.5 below, notwithstanding any request to confirm receipt or acknowledgment contained therein. By its acceptance of such transfer, such FCB Affiliate, on and as of the date of such transfer, hereby makes to the Company each of the representations and warranties set forth in Section 5.1 above and agrees to be bound by all of the terms and conditions of this Warrant as if it were the original Holder hereof.
(c)    Notwithstanding any contrary provision herein, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or knowingly transfer any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company (as determined by the Company’s Board of Directors in its reasonable good faith judgment), except in connection with an Acquisition of the Company by such a direct competitor.”
6.Holder’s address for notices set forth in Section 6.5 is hereby amended and restated in its entirety and replaced with the following:

Active\1609095006.2


“First-Citizens Bank & Trust Company
FCC07 Warrant Investment Team
4300 Six Forks Road
Raleigh, NC 27609
Telephone: (919) 716-7000
Email: fcbwarrants@firstcitizens.com”

7.Appendix 2 in the form attached hereto hereby is added to the Warrant.
8.This Amendment amends certain terms of the Warrant. Company confirms that, except as amended by this Amendment, the Warrant remains in full force and effect and is ratified and confirmed. Unless otherwise defined herein, all capitalized terms in this Amendment shall have the meanings ascribed to them in the Warrant. This Amendment, together with the Warrant, constitutes the entire agreement of the parties with respect to the subject matter hereof, and supersedes all prior agreements and negotiations.
9.This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, and all of which shall constitute one and the same instrument. Each party hereto may execute this Amendment by electronic means and recognizes and accepts the use of electronic signatures and records by any other party hereto in connection with the execution and storage hereof.
10.Time is of the essence for the performance of all obligations set forth in this Amendment.
[Remainder of Page Left Intentionally Blank]

Active\1609095006.2


IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first written above.
COMPANY:                        HOLDER:
AUGMEDIX, INC.    FIRST CITIZENS EQUITY INVESTMENTS, LLC
By:/s/ Paul Ginocchio                    By:/s/ Arch McClure                
Name:    Paul Ginocchio                    Name: Arch McClure
Title:    Chief Financial Officer                Title: Senior Vice President
                                






Active\1609095006.2


APPENDIX 2

Form of Notice of Transfer of Warrant Shares

(by email)

Re:    Response Requested: Transfer of [Additional] Warrant Shares

Dear AUGMEDIX, INC.,

Reference is made to the Warrant to Purchase Stock dated as of __________________________ (the “Warrant”) issued by AUGMEDIX, INC. (“Issuer”), in favor of FIRST CITIZENS EQUITY INVESTMENTS, LLC (“Holder”).

Holder hereby notifies Issuer that, as of ______________________ (the “Transfer Date”), Holder has transferred to ____________________________ (Tax ID: ___________), an FCB Affiliate (“Transferee”), the right to purchase [an additional] ____________________ [common] [preferred] shares of Issuer which are currently exercisable (the “Transferred Shares”) and all rights under the Warrant with respect to such Transferred Shares, pursuant to the transfer provisions contained in the Warrant. [Holder previously transferred to Transferee the right to purchase ____________________ [common] [preferred] shares of Issuer. In the aggregate, Holder has transferred to Transferee, and the Warrant is now exercisable for, a total of ____________________ [common] [preferred] shares of Issuer.]

In connection with such transfer and as of the Transfer Date, Transferee hereby [makes] [reaffirms] to Issuer all representations and warranties set forth in the Warrant applicable to Holder. Furthermore, Transferee [agrees] [reaffirms its agreement] to be bound by all of the terms and conditions of the Warrant applicable to Holder.

Issuer shall note in Issuer’s records and, as applicable, with Issuer’s transfer agent, that Transferee is the “Holder” with respect to the Transferred Shares.

Transferee hereby [notifies] [reaffirms to] Issuer that all notices to Transferee should be addressed to Transferee as follows:

[[Transferee Name]
Attn: _____________________________
[Transferee Address]
Telephone: _________________________
Email: _____________________________]

Please confirm your receipt and acknowledgment of this notice by replying to this email.


Sincerely,

Holder                            Transferee

FIRST-CITIZENS BANK & TRUST COMPANY        [TRANSFEREE NAME]
[Officer Name]                        [Officer Name]
[Officer Title]                        [Officer Title]




Active\1609095006.2





















Active\1609095006.2
EX-10.1 3 exhibit_10x1xsecondamendme.htm EX-10.1 Document


SECOND AMENDMENT
TO
LOAN AND SECURITY AGREEMENT

This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this Agreement”) is entered into as of June 26, 2024, by and between (i) SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (“Bank”), (ii) AUGMEDIX, INC., a Delaware corporation (“Augmedix”), and (iii) AUGMEDIX OPERATING CORPORATION, a Delaware corporation (“Opco” and together with Augmedix, individually and collectively, jointly and severally, “Borrower”).

Recitals
A.    Bank and Borrower have entered into that certain Loan and Security Agreement dated as of May 4, 2022 (as the same may from time to time be amended, modified, supplemented or restated, including, without limitation, by that certain First Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of June 13, 2023, collectively, the “Loan Agreement”). Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.
B.    Borrower has requested that Bank amend the Loan Agreement to make certain revisions to the Loan Agreement as more fully set forth herein. Bank has agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.
Agreement
    Now, Therefore, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:
1.Definitions. Capitalized terms used but not defined in this Agreement shall have the meanings given to them in the Loan Agreement.
2.Omnibus Amendment. All references in the Loan Documents to “Silicon Valley Bank” or “Silicon Valley Bank, a California corporation” shall hereafter mean and refer to “Silicon Valley Bank, a division of First-Citizens Bank & Trust Company”. All references in the Loan Documents to “Bank” shall hereafter mean and refer to “Silicon Valley Bank, a division of First-Citizens Bank & Trust Company”.
3.Amendments to Loan Agreement.
1.1.Section 5.9 (Accounts). Section 5.9(a) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:
“(a)     Maintain account balances in Borrower’s, any of its Subsidiaries’, and any Guarantor’s operating accounts, depository accounts and excess cash with Bank or Bank’s Affiliates representing at least seventy-five percent (75%) of the Dollar Equivalent value of Borrower’s and such Subsidiaries’ and Guarantor’s cash balance at all financial institutions globally. Borrower shall at all times be required to maintain the Cash Collateral Account and the Blocked Account at Bank. Borrower may maintain its Payment Transmitter Accounts, so long as all amounts in excess of Ten Thousand Dollars ($10,000) in such Payment Transmitter Accounts are transferred to Borrower’s deposit accounts at Bank or Bank’s Affiliates every week. The Indian Subsidiary may maintain its Indian Bank Accounts, provided that the total value of all assets held in the Indian Bank Accounts does not exceed, Seven Hundred Fifty Thousand Dollars ($750,000) at any time. The Bangladeshi Subsidiary may maintain its Bangladeshi Bank



Accounts, provided that the total value of all assets held in the Bangladeshi Bank Accounts does not exceed, Two Million Dollars ($2,000,000) at any time.”
1.2.Section 5.10 (Financial Covenants). Section 5.10(a) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:
“(a)     Minimum Revenue. Borrower shall achieve Revenue, to be tested quarterly on the last day of each calendar quarter and measured in accordance with GAAP on a trailing three (3) month basis, in an amount equal to or greater than the corresponding amount set forth in the table below for the applicable measuring period (the “Revenue Covenant”):
Measuring Period Ending Minimum Revenue
June 30, 2024$12,300,000
September 30, 2024$12,800,000
December 31, 2024$13,300,000
March 31, 2025$13,500,000
June 30, 2025$14,800,000
September 30, 2025$16,800,000
December 31, 2025$18,700,000

The required Revenue Covenant levels after December 31, 2025, shall (i) be based on Borrower’s projections delivered to Bank in accordance with Section 5.3(e) hereof and acceptable to Bank in its sole discretion, and (ii) require actual year-over-year Revenue growth acceptable to Bank. The new covenant levels shall be documented in an amendment to this Agreement in form and substance acceptable to Bank which Borrower hereby agrees to execute no later than January 31, 2026. Borrower’s failure to enter into such amendment to this Agreement to reset such covenant levels on or prior to January 31, 2026, shall be an immediate and non-curable Event of Default hereunder.”
3.1.5.20 (Cash Collateralization). New Section 5.20 hereby is added to the Loan Agreement to read in its entirety as follows:
        “5.20     Cash Collateralization. Beginning on the Second Amendment Effective Date and continuing at all times thereafter, Borrower shall maintain at least Five Million Dollars ($5,000,000) in the Blocked Account, which amount shall serve as cash collateral and security for the repayment of the Obligations.”

3.2.Section 12.2 (Definitions). The following terms and their respective definitions hereby are added or amended and restated in their entirety in Section 12.2 of the Loan Agreement, as appropriate, to read as follows:
Blocked Account” means, collectively, each blocked collateral money market account in the name of Borrower maintained at Bank referenced in the Cash Pledge Agreement.
Cash Pledge Agreement” means, collectively, each Bank Services Cash Pledge Agreement, dated as of June 26, 2024, between Borrower and Bank, together with any riders or attachments in connection therewith, and any other Bank Services Cash Pledge Agreement between Borrower and Bank with respect to any Blocked Account.
Collateral” consists of all of Borrower’s right, title and interest in and to the following personal property:
CLOSED\240649613.7


(a)    (i) all goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (except as provided below), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts (including, without limitation, the Blocked Account), certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, securities accounts, securities entitlements and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and (ii) all Borrower’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.
(b)    Notwithstanding anything to the contrary contained herein or in any other Loan Document, in no event shall the Collateral include: (a) rights held under a license that are not assignable by their terms without the consent of the licensor thereof (but only to the extent such restriction on assignment is enforceable under applicable law), (b) any interest of Borrower as a lessee under an Equipment lease if Borrower is prohibited by the terms of such lease from granting a security interest in such lease or under which such an assignment or Lien would cause a default to occur under such lease; provided however, that upon termination of such prohibition, such interest shall immediately become Collateral without any action by Borrower or Bank; or (c) any Intellectual Property; provided, however, the Collateral shall include all Accounts and all proceeds of Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Bank’s security interest in such Accounts and such other property of Borrower that are proceeds of the Intellectual Property.
(c)    Pursuant to the terms of a certain negative pledge arrangement with Bank, Borrower has agreed not to encumber any of its Intellectual Property without Bank’s prior written consent.
Loan Documents” are, collectively, this Agreement and any schedules, exhibits, certificates, notices, and any other documents related to this Agreement, the Perfection Certificate, the Cash Pledge Agreement, the Warrant, any Bank Services Agreement, any subordination agreement, any note, or notes or guaranties executed by Borrower or any Guarantor, landlord waivers and consents, bailee waivers and consents, and any other present or future agreement by Borrower and/or any Guarantor with or for the benefit of Bank in connection with this Agreement or Bank Services, all as amended, restated, or otherwise modified in accordance with the terms thereof.
Payment Transmitter Accounts” means Borrowers payment transmitter accounts at Versa Pay, Tipalti, Expensify, and Ramp as disclosed on the Perfection Certificate dated as of the Second Amendment Effective Date.

        “Second Amendment Effective Date” is June 26, 2024.

3.3.Section 12.2 (Definitions). The following defined terms and their respective definitions hereby are deleted from Section 12.2 and the balance of the Loan Agreement in their entirety:
Equity Milestone 2”, “Interest Adjustment”, “Net Income (Loss)”, “Performance Milestones”, “Performance Milestone 2”, “Performance Milestone 3”, and “Performance Milestone 4”.

3.4.Exhibit A (Compliance Statement). The Compliance Statement set forth in Exhibit A to the Loan Agreement hereby is replaced with Exhibit A attached hereto.
CLOSED\240649613.7


3.5.Schedule I (LSA Provisions). Schedule I to the Loan Agreement hereby is replaced with Schedule I attached hereto.
4.Limitation of Agreement.
4.1.This Agreement is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan Document.
4.2.This Agreement shall be construed in connection with and as part of the Loan Documents, and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.
5.Representations and Warranties. To induce Bank to enter into this Agreement, Borrower hereby represents and warrants to Bank as follows:
5.1.Immediately after giving effect to this Agreement (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Default or Event of Default has occurred and is continuing. Borrower understands and agrees that in modifying the existing Obligations, Bank is relying upon Borrower’s representations, warranties, and agreements, as set forth in the Loan Documents;
5.2.Borrower has the power and authority to execute and deliver this Agreement and to perform its obligations under the Loan Agreement, as amended by this Agreement;
5.3.The organizational documents of Borrower delivered to Bank on the First Amendment Effective Date remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;
5.4.The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Agreement, have been duly authorized by all necessary action on the part of Borrower;
5.5.The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Agreement, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;
5.6.The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Agreement, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and
5.7.This Agreement has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.
6.Ratification of Perfection Certificate.  In connection with this Agreement, Borrower has delivered an updated Perfection Certificate (the “Updated Perfection Certificate”). Borrower and Bank acknowledge and agree
CLOSED\240649613.7


that, from and after the date of this Agreement, each reference in the Loan Documents to the “Perfection Certificate” or the “Perfection Certificate dated as of the Effective Date” shall be deemed to be a reference to the Updated Perfection Certificate. Borrower acknowledges, confirms and agrees the disclosures and information Borrower provided to Bank in the Updated Perfection Certificate have not changed as of the date hereof.
7.Prior Agreement. The Loan Documents are hereby ratified and reaffirmed and shall remain in full force and effect. Borrower hereby ratifies, confirms, and reaffirms all terms and conditions of all security or other collateral granted to the Bank, and confirms that the indebtedness secured thereby includes, without limitation, the Obligations. This Agreement is not a novation and the terms and conditions of this Agreement shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. In the event of any conflict or inconsistency between this Agreement and the terms of such documents, the terms of this Agreement shall be controlling, but such document shall not otherwise be affected or the rights therein impaired.
8.Integration. Except as expressly modified pursuant to this Agreement, the terms of the Loan Documents remain unchanged and in full force and effect. This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.
9.Fees and Expenses. Borrower shall pay to Bank on the date first listed above (a) all Bank Expenses due and owing as of the date hereof. The fees and expenses listed in the previous sentence may be debited from any of Borrower’s accounts at Bank.
10.Conditions to Effectiveness. The parties agree that the obligations of Bank herein shall be effective upon the satisfaction of each of the following conditions precedent, each in form and substance satisfactory to Bank in its sole discretion, on or prior to the date first listed above:
10.1.the due execution and delivery to Bank of this Agreement by each party hereto;
10.2.the due execution and delivery to Bank of the Cash Pledge Agreement (including Rider) by each party thereto;
10.3.the due execution and delivery to Bank of the First Amendment to Warrant to Purchase Stock; and
10.4.Bank’s receipt of such other documents, instruments and agreements as Bank may reasonably request to effectuate the terms of this Agreement.
11.Miscellaneous.
11.1.This Agreement shall constitute a Loan Document under the Loan Agreement; the failure to comply with the covenants contained herein shall constitute an Event of Default under the Loan Agreement; and all obligations included in this Agreement (including, without limitation, all obligations for the payment of principal, interest, fees, and other amounts and expenses) shall constitute obligations under the Loan Agreement and secured by the Collateral.
11.2.Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.
11.3.This Agreement may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.
11.4.The Loan Documents are hereby amended wherever necessary to reflect the changes described above.
CLOSED\240649613.7


11.5.Section 11.9 of the Loan Agreement applies to this Agreement.
11.6.This Agreement and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.
12.Post-Closing Obligations.
12.1.As soon as possible, but in any event no later than forty-five (45) days after the Second Amendment Effective Date, Borrower shall deliver to Bank evidence that the tax lien in favor of the California Department of Tax and Fee Administration in the amount of Two Thousand Six Hundred Eight Dollars and Sixty-Four Cents ($2,608.64), instrument no. U230075390833, filed 10/19/23, has been terminated.
1.3.As soon as possible, but in any event no later than forty-five (45) days after the Second Amendment Effective Date, Borrower shall deliver to Bank a duly executed Control Agreement with Comerica Bank with respect to Borrower’s account number ending in 8446 at Comerica Bank as disclosed on the Perfection Certificate dated as of the Second Amendment Effective Date.

[Signature page follows.]
CLOSED\240649613.7


In Witness Whereof, the parties hereto have caused this Agreement to be duly executed and delivered as of the date first written above.


BANKBORROWER

FIRST-CITIZENS BANK & TRUST COMPANY


By:  /s/ Matthew Perry            
Name:  Matthew Perry 
Title:   Managing Director 

AUGMEDIX, INC.


By:  /s/ Paul Ginocchio            
Name:  Paul Ginocchio
Title:   Chief Financial Officer    

AUGMEDIX OPERATING CORPORATION


By:  /s/ Manny Krakaris            
Name:  Manny Krakaris
Title:   Chief Executive Officer





































CLOSED\240649613.7



[Signature Page to Second Amendment to Loan and Security Agreement]

SCHEDULE I
LSA PROVISIONS

LSA SectionLSA Provision
1.1(a) – Revolving Line – AvailabilityAmounts borrowed under the Revolving Line may be prepaid or repaid and, prior to the Revolving Line Maturity Date, reborrowed, subject to the applicable terms and conditions precedent herein.
1.2(a) – Term Loan – AvailabilityEach Tranche B Term Loan Advance must be in an amount equal to at least One Million Dollars ($1,000,000). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed.
1.2(b) – Term Loan – RepaymentCommencing on the Term Loan Amortization Date and continuing on each Payment Date thereafter, Borrower shall repay each Term Loan Advance in (i) twenty-four (24) equal monthly installments of principal, which shall, upon Borrower’s request, reduce to eighteen (18) equal monthly installments of principal if Bank chooses to extend the Term Loan Amortization Date in accordance with the terms hereof in its sole and absolute discretion, plus (ii) monthly payments of accrued interest at the rate set forth in Section 1.4(b)(ii).
1.4(a)(i) – Interest Payments – AdvancesInterest on the principal amount of each Advance is payable in arrears monthly (i) on each Payment Date, (ii) on the date of any prepayment and (iii) on the Revolving Line Maturity Date.
1.4(a)(ii) – Interest Payments – Term Loan AdvancesInterest on the principal amount of each Term Loan Advance is payable in arrears monthly (i) on each Payment Date commencing on the first Payment Date following the Funding Date of each such Term Loan Advance, (ii) on the date of any prepayment and (iii) on the Term Loan Maturity Date.
1.4(a)(i)– Interest Rate – Advances
The outstanding principal amount of any Advance shall accrue interest at a floating rate per annum equal to the greater of (A) six and one-half of one percent (6.50%) and (B) the Prime Rate plus the Prime Rate Margin, which interest shall be payable in accordance with Section 1.4(a).
1.4(b)(ii) – Interest Rate – Term Loan AdvancesThe outstanding principal amount of any Term Loan Advance shall accrue interest at a floating rate per annum equal to the greater of (A) six percent (6.00%) and (B) the Prime Rate plus the Prime Rate Margin, which interest shall be payable in accordance with Section 1.4(a).
1.4(e) – Interest ComputationInterest shall be computed on the basis of the actual number of days elapsed and a 360-day year for any Credit Extension outstanding.
CLOSED\240649613.7


1.5(a) – Revolving Line Commitment Fee
A fully earned, non-refundable commitment fee of Fifty Thousand Dollars ($50,000) (the “Revolving Line Commitment Fee”) on the Effective Date.
8.8– Borrower LiabilityEach Borrower hereunder shall be jointly and severally obligated to repay all Credit Extensions made hereunder and any other Obligations related thereto, regardless of which Borrower actually receives said Credit Extension, as if each Borrower hereunder directly received all Credit Extensions.
12.2 – “Borrower”
Borrower” means, jointly and severally, individually and collectively, each of (i) AUGMEDIX, INC., a Delaware corporation, and (ii) AUGMEDIX OPERATING CORPORATION, a Delaware Corporation.
12.2 – “Effective Date”
Effective Date” is May 4, 2022.
12.2 – “Payment Date”
Payment Date” is (a) with respect to Term Loan Advances, the first (1st) calendar day of each month and (b) with respect to Advances, the last calendar day of each month.
12.2 – “Prime Rate”
 “Prime Rate” is the rate of interest per annum from time to time published in the money rates section of The Wall Street Journal or any successor publication thereto as the “prime rate” then in effect; provided that if such rate of interest, as set forth from time to time in the money rates section of The Wall Street Journal, becomes unavailable for any reason as determined by Bank, the “Prime Rate” shall mean the rate of interest per annum announced by Bank as its prime rate in effect at its principal office in the State of California (such Bank announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit to debtors); provided that, in the event such rate of interest is less than zero percent (0.0%) per annum, such rate shall be deemed to be zero percent (0.0%) per annum for purposes of this Agreement.
12.2 – “Prime Rate Margin”
Prime Rate Margin” is (a) for Advances, one-half of one percent (0.50%), and (b) for Term Loan Advances, zero percent (0.0%).
12.2 – “Revolving Line”
Revolving Line” is an aggregate principal amount equal to (a) at all times prior to completion of the Initial Audit, Two Million Five Hundred Thousand Dollars ($2,500,000), and (b) at all times after completion of the Initial Audit, Five Million Dollars ($5,000,000).
12.2 – “Revolving Line Maturity Date”
Revolving Line Maturity Date” is November 4, 2024; provided however, upon Borrower’s request, Bank, in its sole and absolute discretion, may extend the Revolving Line Maturity Date to November 4, 2025. For the avoidance of doubt, Bank is under no obligation to extend the Revolving Line Maturity Date past November 4, 2024.
CLOSED\240649613.7


12.2 – “Term Loan Amortization Date”
Term Loan Amortization Date” is, for each Term Loan Advance, January 1, 2025; provided however, upon Borrower’s request, the Term Loan Amortization Date may be extended by Bank, in its sole and absolute discretion, to July 1, 2025. For the avoidance of doubt, Bank is under no obligation to extend the Term Loan Amortization Date past January 1, 2025.
12.2 – “Term Loan Availability Amount”
Term Loan Availability Amount” is an aggregate principal amount equal to Twenty Million Dollars ($20,000,000).
12.2 – “Term Loan Maturity Date”
Term Loan Maturity Date” is December 1, 2026.
12.2 – “Tranche B Draw Period”
Tranche B Draw Period” means the period commencing on the date on which Borrower achieves the Performance Milestone and ending on the earlier to occur of (i) December 31, 2023 or (ii) at the option of Bank, the date on which an Event of Default occurs hereunder.


EXHIBIT A
COMPLIANCE STATEMENT
TO:    SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company
FROM:    AUGMEDIX, INC., on behalf of all Borrowers
Date:         

Under the terms and conditions of the Loan and Security Agreement between Borrower and Bank (as amended, modified, supplemented and/or restated from time to time, the “Agreement”), Borrower is in complete compliance for the period ending _______________ with all required covenants except as noted below. Attached are the required documents evidencing such compliance, setting forth calculations prepared in accordance with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement.
Please indicate compliance status by circling Yes/No under “Complies” column.
Reporting CovenantsRequiredComplies

Quarterly financial statements with Compliance StatementQuarterly within (i) 45 days after the last day of the first three calendar quarters of each fiscal year, and (ii) ninety (90) days after the last day of the last fiscal quarter of each fiscal yearYes No
Annual financial statements (CPA Audited)FYE within 180 daysYes No
10-Q, 10-K and 8-KWithin 5 days after filing with SECYes No
Borrowing Base Statements(i) monthly within 30 days of month end when a Streamline Period is in effect, (ii) weekly on Friday of each week when a Streamline Period is not in effect, and (iii) with each request for an AdvanceYes No
A/R & A/P AgingsMonthly within 30 daysYes No
CLOSED\240649613.7


Board approved projectionsFYE within 30 days and as amended/updatedYes No
Board Materials Within 30 days of presentation to the BoardYes No
Monthly bank statements for accounts outside of BankMonthly within 30 daysYes No

Financial Covenant
RequiredActualComplies
Maintain as indicated:
Minimum Revenue
See
Schedule 1
$__Yes No

Other Matters

Have there been any amendments of or other changes to the capitalization table of Borrower and to the Operating Documents of Borrower or any of its Subsidiaries? If yes, provide copies of any such amendments or changes with this Compliance Statement.YesNo

Accounts:
1.Borrower’s total balance, including cash, in accounts in the name of Borrower maintained with Bank or Bank’s Affiliates: $________________
2.Total aggregate balance, including cash, of Borrower at all institutions wherever located: $_______________
3.Is Borrower’s balance, including cash, in accounts in the name of Borrower maintained with Bank or Bank’s Affiliates greater than or equal to 75% of the total aggregate balance, including cash, of Borrower at all institutions wherever located?
Yes, in compliance ______________        No, not in compliance ____________
4.Institutions (other than Bank) where Borrower maintains accounts and balances in such accounts:
Institution NameAccount NumberBalanceControl Agreement in favor of Bank obtained?

Yes, in compliance ______________        No, not in compliance ____________
5.To the extent a Subsidiary exists, please also answer questions #1 through #4 above as to each such Subsidiary.
    The following financial covenant and Streamline Period analysis and information set forth in Schedule 1 attached hereto are true and correct as of the date of this Compliance Statement.
CLOSED\240649613.7


    The following are the exceptions with respect to the statements above: (If no exceptions exist, state “No exceptions to note.”)

CLOSED\240649613.7


Schedule 1 to Compliance Statement
Financial Covenant and Streamline Period Analysis of Borrower
In the event of a conflict between this Schedule and the Agreement, the terms of the Agreement shall govern.
Dated:    ____________________
I.    Minimum Revenue (Section 5.10)
Required: See chart below
Measuring Period Ending Minimum Revenue
June 30, 2024$12,300,000
September 30, 2024$12,800,000
December 31, 2024$13,300,000
March 31, 2025$13,500,000
June 30, 2025$14,800,000
September 30, 2025$16,800,000
December 31, 2025$18,700,000

Actual: $_____________

Is Borrower’s actual Revenue greater than or equal to the required amount for the corresponding measuring period set forth in the chart above?

          No, not in compliance                      Yes, in compliance

II. Streamline Period Compliance
Required:    ≥1.35:1.00
Actual:
A.Aggregate value of the Borrower’s unrestricted and unencumbered (except for Liens in favor of Bank) cash and Cash Equivalents held at Bank and Bank’s Affiliates $    
B.Aggregate value of Borrower’s net Eligible Accounts$    
C.Quick Assets (the sum of lines A through B)$    
D.Aggregate value of Obligations owing from Borrower to Bank under the Revolving Line $    

CLOSED\240649613.7


E.Aggregate value of liabilities of Borrower and its Subsidiaries (including all Indebtedness/Term Loan Advances) that matures within one (1) year (without duplication with line D above)$    
F.Current Liabilities (the sum of lines D and E)    $    
G.
Aggregate value of all amounts received or invoiced by Borrower in advance
of performance under contracts and not yet recognized as revenue
$______
H.Line F minus Line G $______
I.Adjusted Quick Ratio (line C divided by line H)
Is line I equal to or greater than or equal to 1.35:1:00?

          No, not in compliance                          Yes, in compliance






CLOSED\240649613.7
EX-101.SCH 4 augx-20240626.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 augx-20240626_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Ex Transition Period Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cover [Abstract] Cover [Abstract] Written Communications Written Communications Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security City Area Code City Area Code Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 augx-20240626_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 26, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 26, 2024
Entity Registrant Name AUGMEDIX, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40890
Entity Tax Identification Number 83-3299164
Entity Address, Address Line One 111 Sutter Street
Entity Address, Address Line Two Suite 1300
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code 888
Local Phone Number 669-4885
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AUGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001769804
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://augmedix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports augx-20240626.htm augx-20240626.xsd augx-20240626_lab.xml augx-20240626_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "augx-20240626.htm": { "nsprefix": "augx", "nsuri": "http://augmedix.com/20240626", "dts": { "inline": { "local": [ "augx-20240626.htm" ] }, "schema": { "local": [ "augx-20240626.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "augx-20240626_lab.xml" ] }, "presentationLink": { "local": [ "augx-20240626_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://augmedix.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "augx-20240626.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "augx-20240626.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://augmedix.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001628280-24-030175-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-030175-xbrl.zip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end XML 18 augx-20240626_htm.xml IDEA: XBRL DOCUMENT 0001769804 2024-06-26 2024-06-26 false 0001769804 8-K 2024-06-26 AUGMEDIX, INC. DE 001-40890 83-3299164 111 Sutter Street Suite 1300 San Francisco CA 94104 888 669-4885 false false false false Common Stock, $0.0001 par value per share AUGX NASDAQ true false